Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
For the gastric cancer, paclitaxel is recommended as salvage standard treatment. Afatinib is
a novel, potent, small ErbB family blocker that covalently binds and irreversibly blocks
signaling through activated EGFR, HER2 and ErbB4 receptors, as well as the
transphosphorylation of ErbB3. The investigators suggest a randomized phase II trial of
afatinib plus weekly taxol(paclitaxel) for previously treated EGFR positive gastric cancer
patients. The aim of current trial is to evaluate the antitumor efficacy of afatinib for
target enriched patients in gastric cancer.